- Home
- About
- WEST Events
- Sponsorship
- Membership
- Volunteers
- Resources
- Blog
The Investor's Perspective
|
Paulina Hill, Senior Associate, Polaris Partners Paulina joined Polaris in 2011 and focuses on investments in healthcare. Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. In the laboratory of Bob Langer, Paulina worked on developing novel biomaterial scaffolds and drug delivery systems for neural applications. Paulina is the founding president of the MIT Postdoctoral Association, was nominated to and serves on the MIT Intellectual Property Presidential Committee, and is on the fundraising committee of the nonprofit Women Entrepreneurs in Science & Technology. Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Her graduate school work resulted in over 40 published abstracts, awards and peer reviewed manuscripts. Her research contributed to numerous patents and the formation of the startup KeraNetics to commercialize the platform technology. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. |
|
Jean Hammond, Partner, LearnLaunchX |
|
Jean George, General Partner of Advanced Technology Ventures (ATV) Jean is a General Partner of Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. She is based in the firm’s Boston office, where she also serves as a General Partner for Lightstone Ventures. Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates. Prior to ATV, Jean led life science investments for BancBoston Ventures. Previously, Jean spent six years working in chemistry and bioresearch. Jean earned an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine. |
|
Panel Discussion Moderator Alexandra is Chief Operating Officer at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of genetic diseases. Alexandra was most recently Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. She was brought in by founders and investors to help build Tempo (renamed Cerulean) from the ground up. She was a key contributor to all aspects of building the company including setting the strategy, analyzing product development opportunities, cultivating platform and product partnership prospects and participating in fundraising activities. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and M&A efforts. During her tenure at Millennium, Alexandra was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated and commercial pharmaceuticals company. Her division played an integral role in the numerous Millennium-large pharma collaborations, which generated over $1.8 billion in funding for the company. She serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women in the Enterprise of Science and Technology (WEST). She is also a member of the Advisory Council of the Harvard Partners Center for Personalized Genetic Medicine. Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago. |
Download the event invitation here.
Date and Time:
March 4, 2014
6:00 - 9:00 PM
Location:
Microsoft New England Research and Development Center, 1 Memorial Drive, Abigail Adams & Crispus Attucks rooms, Cambridge, MA
We appreciate Microsoft New England Research and Development Center donating the use of their event space.
WEST's Entrepreneurial Series has multiple events including The Entrepreneurial Mindset and Resiliency on March 11, 2014 and a Fireside Chat on Entrepreneurial Leadership in May 2014.
If you are a student looking for financial assistance to attend this event, please visit www.stayinma.com.